Home  |  Contact

UniProtKB/Swiss-Prot Q9BZW4: Variant p.Glu167Lys

Transmembrane 6 superfamily member 2
Gene: TM6SF2
Variant information

Variant position:  167
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glutamate (E) to Lysine (K) at position 167 (E167K, p.Glu167Lys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (E) to large size and basic (K)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  Common polymorphism; associated with higher circulating levels of alanine transaminase with lower levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides and alkaline phosphatase in 3 independent populations; reduces protein expression by 46%.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  167
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  377
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.




Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 377 Transmembrane 6 superfamily member 2
Domain 61 – 186 EXPERA 1

Literature citations

Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk.
Holmen O.L.; Zhang H.; Fan Y.; Hovelson D.H.; Schmidt E.M.; Zhou W.; Guo Y.; Zhang J.; Langhammer A.; Lochen M.L.; Ganesh S.K.; Vatten L.; Skorpen F.; Dalen H.; Zhang J.; Pennathur S.; Chen J.; Platou C.; Mathiesen E.B.; Wilsgaard T.; Njolstad I.; Boehnke M.; Chen Y.E.; Abecasis G.R.; Hveem K.; Willer C.J.;
Nat. Genet. 46:345-351(2014)
Cited for: VARIANT LYS-167;

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.
Kozlitina J.; Smagris E.; Stender S.; Nordestgaard B.G.; Zhou H.H.; Tybjaerg-Hansen A.; Vogt T.F.; Hobbs H.H.; Cohen J.C.;
Nat. Genet. 46:352-356(2014)

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
Liu Y.L.; Reeves H.L.; Burt A.D.; Tiniakos D.; McPherson S.; Leathart J.B.; Allison M.E.; Alexander G.J.; Piguet A.C.; Anty R.; Donaldson P.; Aithal G.P.; Francque S.; Van Gaal L.; Clement K.; Ratziu V.; Dufour J.F.; Day C.P.; Daly A.K.; Anstee Q.M.;
Nat. Commun. 5:4309-4309(2014)
Cited for: VARIANT LYS-167;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.